Editor's Note Recently Asa Waldstein (chair of AHPA's Cannabis Committee), Michael McGuffin (AHPA President), and Johnel Lagabon (Engagement Manager at Burdock Group) sat down to talk about what hemp cannabinoid companies should be doing to prepare for FDA regulations. Their thoughtful discussion provides insights from legislative, scientific, and practical points of view. Take a look at what these three had to say here.

Preparing for Cannabinoid Regulations: An NDI Focused Conversation May 4, 2021 Asawaldstein.com Full Video  Discussion Highlights  2:11​ Michael McGuffin’s thoughts on HR 841, and what does this mean for hemp companies if it passes? 5:03​ What is the difference between NDIN’s and GRAS? 9:09​ Why choose self-GRAS or FDA-GRAS? 22:51​ What can companies be doing now to prepare for the future? 31:01​ What NDI responsibilities do extract suppliers have versus manufacturers of a finished product? 35:20​ If a company does self-GRAS do they need to submit an NDIN? 36:45​ What is the risk or penalties associated with introducing an NDI into commerce without going through the NDIN process? 40:44​ What role does real world data being collected by companies like ValidCare play in the NDIN or GRAS process? 42:31​ What practical steps will small-scale producers of CBD oils and salves need to do? 43:46​ Will naturally occurring cannabinoid profiles in a full or CO2 extract require an NDIN?

2021 Annual Fund Sponsors:

Visit our website

‌ ‌ ‌ ‌